National development projects for precision diagnostics of solid tumors in Sweden

Genomic Medicine Sweden (GMS) is a national initiative established in 2018 with the goal of translating innovations in genomics into clinical practice. The initiative focuses on implementing large-scale, next-generation sequencing (NGS) techniques within healthcare and establishing a sustainable infrastructure for precision medicine.

On October 20, 2025, GMS announced the launch of five strategic development projects, supported by the Ministry of Health and Social Affairs, aimed at expanding access to advanced diagnostics nationwide.

The projects are coordinated through Genomic Medicine Centers (GMCs), where clinicians and researchers collaborate to advance and implement precision medicine. The initiative encompasses both the development of new analytical tools and the scaling up of existing methods for broader clinical use.

The projects focus on the following areas:

• Updating the national GMS gene panel for solid tumors (DNA and RNA panels): The goal is to include clinically relevant biomarkers and harmonize panel content across the country to enable wider clinical implementation.
• Liquid biopsies – an alternative when tissue is difficult to access: This project will validate the existing tissue-based gene panel for use with cell-free tumor DNA (ctDNA) in plasma, supporting its clinical adoption.
• Metastatic breast cancer – genetic analysis at diagnosis and follow-up via ctDNA: For patients newly diagnosed with metastatic breast cancer, comprehensive genetic analysis of tumor tissue will be performed at diagnosis. Because the tumor’s genetic profile may change over time, follow-up analysis using ctDNA from blood samples will be conducted. This approach enables the rapid detection of treatment-relevant mutations throughout the disease course.
• Advanced profiling of hepatopancreatobiliary (HPB) cancers: For challenging cancers of the pancreas, liver, and bile ducts, broad molecular profiling is often essential to guide treatment. This project aims to further develop testing using extensive gene panels to increase access to precision diagnostics and novel therapeutic options.
• Sarcoma – genetic mapping of a heterogeneous tumor group: Sarcomas are rare and genetically diverse tumors that present significant diagnostic challenges. By comparing whole-genome sequencing data with results from nationally developed DNA and RNA panels, this project seeks to enhance diagnostic accuracy and support the introduction of new methods into routine clinical care.

The full details in Swedish can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.